Immune-tox
Research type
Research Study
Full title
Immune-tox: A prospective observational study of acute, chronic and late adverse effects from immune checkpoint inhibitors in patients with melanoma.
IRAS ID
328493
Contact name
Rebecca Lee
Contact email
Sponsor organisation
University of Manchester
Duration of Study in the UK
6 years, 11 months, 31 days
Research summary
Immune checkpoint inhibitors (ICIs) enhance the immune system’s ability to fight cancer. Due to their effectiveness, there is a growing population of patients with melanoma expected to live for many years after treatment with ICIs. Evidence regarding long-term effects of these treatments is limited.
The Immune-Tox study aims to characterise long-term effects from ICIs in patients with melanoma. We will recruit patients who received an ICI after having had melanoma surgically removed. We will monitor patients for several years and compare them to patients who did not receive ICIs to assess any difference in the rate of cardiac and other medical conditions, as well as assessing quality of life and energy/fatigue. This information will inform patient-clinician discussions about the risks and benefits of ICIs, improving monitoring, prevention and management of late effects. This will allow more informed decision making and potentially improve long-term quality of life of patients with melanoma.
REC name
West of Scotland REC 5
REC reference
24/WS/0101
Date of REC Opinion
30 Aug 2024
REC opinion
Further Information Favourable Opinion